Decitabine in combination with R-CHOP
Phase 3Small molecule
Decitabine in combination with R-CHOP is one of 51 small molecule programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
332 competitors in Diffuse Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Rituxan
RochePhase 3
Gemzar
Johnson & JohnsonPhase 3
Gazyva
RochePhase 3
Eloxatin
TevaPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
COLUMVI
RochePhase 3
Cytosar
TevaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Diffuse Large B-Cell Lymphoma1 trial
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
Enrolling by invitation·SSecond Affiliated Hospital of Nanchang University·Phase 3·NCT07348575·80 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details